<DOC>
	<DOCNO>NCT00944554</DOCNO>
	<brief_summary>This study aim determine varenicline ( ChantixÂ® ) , currently use smoke cessation aid , decrease likelihood relapse smoke follow programmed lapse laboratory . The hypothesis varenicline reduce reinforce effect smoke delay prevent relapse compare placebo .</brief_summary>
	<brief_title>Relapse Prevention With Varenicline</brief_title>
	<detailed_description>In study , investigator plan use experimental model lapse , volunteer smoke two cigarette brief period ( 12-24 hour ) . The goal study assess impact varenicline subjective reinforcing effect cigarette , well latency resume smoke ( relapse ) follow lapse exposure .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Age 1875 year old Reports smoke least 10 cigarette per day AND provide urine sample test positive nicotine metabolite intake Contemplating smoke cessation attempt near future Willing engage practice quit attempt ask smoke one occasion Able give inform consent Currently meet DSMIV criterion depression , bipolar disorder , schizophrenia History attempt suicide express current suicidal ideation Pregnant , breast feeding , plan become pregnant within next 3 month Reports desire immediate treatment tobacco/nicotine dependence Severe impairment renal function indicate GFR le 30 ml/min calculate use Cockcroft Gault prediction method ( plasma creatinine adjust weight , gender , age )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Smoking Cessation</keyword>
	<keyword>Substance Abuse</keyword>
</DOC>